Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

MGFB: vaccinating against tumor antigen escape

The Greenfire Bio subsidiary is developing xenogenic tumor antigen libraries delivered via engineered viruses

By Richard Guy, Biopharma Analyst
November 16, 2022 7:30 PM UTC

MGFB is developing virus-based cancer vaccines for solid tumors that prime the immune system against hundreds of tumor antigens, including ones that arise during tumor escape, and aims to achieve stronger immune responses by tapping non-human cDNA systems.

The clinical-stage company, a subsidiary of Greenfire Bio, launched Nov. 8 with technology licensed from Richard Vile’s lab at the Mayo Clinic.  ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Greenfire Bio

Nouscom AG